Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Hematological cancer in 2011

New therapeutic targets and treatment strategies

Nature Reviews Clinical Oncology volume 9, pages 72–74 (2012)Cite this article

Subjects

2011 saw improvements in our understanding of B-cell malignancies: insights into the genomic basis of chronic lymphocytic leukemia were achieved; reduced treatment intensity caused fewer toxic effects in early-stage Hodgkin lymphoma; first-line rituximab maintenance therapy improved outcome in follicular lymphoma; and selected patients with diffuse large-cell lymphoma benefited from the addition of bortezomib.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kikushige, Y. et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246–259 (2011).

    Article  CAS  Google Scholar 

  2. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101–105 (2011).

    Article  CAS  Google Scholar 

  3. Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1109016.

  4. Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42–51 (2011).

    Article  CAS  Google Scholar 

  5. Bachy, E. et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - a study from the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 28, 822–829 (2010).

    Article  Google Scholar 

  6. Engert, A. et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma N. Engl. J. Med. 363, 640–652 (2010).

    Article  CAS  Google Scholar 

  7. Borchmann, P. et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J. Clin. Oncol. 29, 4234–4242 (2011).

    Article  CAS  Google Scholar 

  8. Viviani, S. et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203–212 (2011).

    Article  CAS  Google Scholar 

  9. Ruan, J. et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 690–697 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I and Center for Integrated Oncology Köln-Bonn, University of Cologne, Joseph-Stelzmann-Straße. 9, Cologne, 50924, Germany

    Paula Cramer & Michael Hallek

Authors
  1. Paula Cramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Hallek.

Ethics declarations

Competing interests

M. Hallek acts as a consultant for and has received honoraria and research support from Celgene, Mundipharma and Roche. P. Cramer declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cramer, P., Hallek, M. New therapeutic targets and treatment strategies. Nat Rev Clin Oncol 9, 72–74 (2012). https://doi.org/10.1038/nrclinonc.2011.212

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.212

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing